1、2023ANNUAL REPORTFiscal year ending March 31Advancing health outcomes for all45M+prescription deliveries per yearStrength in Distribution99.9%pharmaceutical order accuracy in North America275,000+customers served with medical-surgical productsSuperior Specialty AssetsUS Oncology Research has played

2、a role in 100 FDA-approved cancer therapiesSupported 3,500 specialty practices with 170 cancer and rare/complex disease medications and supportive therapiesLeading distributor in community oncology and specialty therapiesTechnology DifferentiationConnected to payers representing 94%of U.S.prescripti

3、on volumeAccess to research data from 2.5M records including 80 oncology indicationsBiopharma ServicesMore than 650 biopharma brands servedIncreased value to biopharma and enabled$8B in prescription savings95%of therapeutic areasSupportedNetwork of 900,000+providers and over 50,000 pharmaciesWe help

4、 advance health outcomes for a better tomorrow To our valued shareholders:?for McKesson as we continued to advance our leading?Further differentiating ourselves from our competitors,we maintained our performance?earnings per diluted share by 9%versus the prior year,driven by focused execution on our

5、?Building on the strength of our core businesses,we made progress advancing our strategic growth?of cancer,diversifying the healthcare talent pipeline and accelerating emergency preparedness?McKesson Strategy?1|?enhanced our employee experience by introducing pay-range transparency?In addition,we ch

6、ampioned new programs and resources to promote the?pilot in six of our distribution centers to help employees better navigate?The future of health starts with you,?2|?Platforms?invest and accelerate execution in our two strategic growth areas,?at expanding clinical research,accelerating drug develop